Synchronous Mesonephric-like Adenocarcinoma and Endometrioid Borderline Tumour in Bilateral Ovaries: A Case Report
article
OA: gold
CC0
Abstract
Mesonephric Like Adenocarcinoma (MLA) is a rare aggressive carcinoma recognised in the 2020 WHO classification, with fewer than 200 cases reported worldwide. It shows KRAS mutations in 70-81% of cases, a strong association with endometriosis (50- 70%), and a characteristic immunoprofile (PAX8+, TTF1+, GATA3 patchy+, ER-, WT1-). The histogenesis of MLA is increasingly linked to Müllerian epithelium, often in association with endometriosis. The coexistence of an MLA and an endometrioid borderline tumour within bilateral ovaries is exceedingly rare and provides further evidence of divergent Müllerian differentiation. This is a case report of a 45-year-old nulliparous woman presenting with abdominal pain and bilateral ovarian masses. Preoperative serum Carcinoembryonic Antigen (CA)-125 was 455 U/mL and CA 19-9 was 346 U/mL. Intraoperative frozen section of the left ovarian mass indicated an epithelial malignancy. Permanent section analysis confirmed MLA in the left ovary (PAX8+, TTF1 strong+, GATA3 patchy+, ER–, WT1–, wild-type p53). The right ovary harbored an endometrioid borderline tumour (PAX8+, ER+, TTF1–, GATA3–, wild-type p53). Endometriosis was concurrently identified in both ovaries and fallopian tubes. The patient underwent complete staging surgery followed by chemotherapy and remains clinically and radiologically disease-free at the time of reporting. This case highlights the critical role of comprehensive immunohistochemical profiling in the precise diagnosis of rare ovarian tumours and provides further evidence supporting a Müllerian origin for MLA.
Full text
2,910 characters
· extracted from
oa-html
· click to expand
Synchronous Mesonephric-like Adenocarcinoma and Endometrioid Borderline Tumour in Bilateral Ovaries: A Case Report
Correspondence Address :
Dr. Pritam Ray,
360, Panchasayar Road, Kolkata-700094, West Bengal, India.
E-mail: [email protected]
Mesonephric Like Adenocarcinoma (MLA) is a rare aggressive carcinoma recognised in the 2020 WHO classification, with fewer than 200 cases reported worldwide. It shows KRAS mutations in 70-81% of cases, a strong association with endometriosis (50-70%), and a characteristic immunoprofile (PAX8+, TTF1+, GATA3 patchy+, ER-, WT1-). The histogenesis of MLA is increasingly linked to Müllerian epithelium, often in association with endometriosis. The coexistence of an MLA and an endometrioid borderline tumour within bilateral ovaries is exceedingly rare and provides further evidence of divergent Müllerian differentiation. This is a case report of a 45-year-old nulliparous woman presenting with abdominal pain and bilateral ovarian masses. Preoperative serum Carcinoembryonic Antigen (CA)-125 was 455 U/mL and CA 19-9 was 346 U/mL. Intraoperative frozen section of the left ovarian mass indicated an epithelial malignancy. Permanent section analysis confirmed MLA in the left ovary (PAX8+, TTF1 strong+, GATA3 patchy+, ER–, WT1–, wild-type p53). The right ovary harbored an endometrioid borderline tumour (PAX8+, ER+, TTF1–, GATA3–, wild-type p53). Endometriosis was concurrently identified in both ovaries and fallopian tubes. The patient underwent complete staging surgery followed by chemotherapy and remains clinically and radiologically disease-free at the time of reporting. This case highlights the critical role of comprehensive immunohistochemical profiling in the precise diagnosis of rare ovarian tumours and provides further evidence supporting a Müllerian origin for MLA.
Endometrioid borderline tumour, Immunohistochemistry, Mesonephric-like adenocarcinoma, Ovarian neoplasms
DOI: 10.7860/JCDR/2026/84157.22744
Date of Submission: Sep 12, 2025
Date of Peer Review: Oct 18, 2025
Date of Acceptance: Dec 31, 2025
Date of Publishing: Apr 01, 2026
AUTHOR DECLARATION:
• Financial or Other Competing Interests: None
• Was informed consent obtained from the subjects involved in the study? Yes
• For any images presented appropriate consent has been obtained from the subjects. Yes
PLAGIARISM CHECKING METHODS:
• Plagiarism X-checker: Sep 21, 2025
• Manual Googling: Dec 27, 2025
• iThenticate Software: Dec 29, 2025 (1%)
ETYMOLOGY: Author Origin
EMENDATIONS: 7
- Emerging Sources Citation Index (Web of Science, thomsonreuters)
- Index Copernicus ICV 2017: 134.54
- Academic Search Complete Database
- Directory of Open Access Journals (DOAJ)
- Embase
- EBSCOhost
- Google Scholar
- HINARI Access to Research in Health Programme
- Indian Science Abstracts (ISA)
- Journal seek Database
- Popline (reproductive health literature)
- www.omnimedicalsearch.com
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Ask this paper
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Condition tags
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.
Source provenance
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0
· commercial use OK